CELU - Celularity Inc. Stock Price, Fair Value and News

3.38USD+0.17 (+5.30%)Market Closed

Market Summary

USD3.38+0.17

Market Closed

5.30%

CELU Stock Price

View Fullscreen

CELU RSI Chart

CELU Valuation

Market Cap

622.0M

Price/Earnings (Trailing)

-3.77

Price/Sales (Trailing)

46.26

EV/EBITDA

-0.56

Price/Free Cashflow

-10.5

CELU Price/Sales (Trailing)

CELU Profitability

EBT Margin

-1226.64%

Return on Equity

-599.76%

Return on Assets

-115.41%

Free Cashflow Yield

-9.53%

CELU Fundamentals

CELU Revenue

Revenue (TTM)

14.8M

Rev. Growth (Yr)

-8.44%

Rev. Growth (Qtr)

28.86%

CELU Earnings

Earnings (TTM)

-181.4M

Earnings Growth (Yr)

-2.1K%

Earnings Growth (Qtr)

-95.78%

Breaking Down CELU Revenue

Last 7 days

-6.6%

Last 30 days

-37.0%

Last 90 days

990%

Trailing 12 Months

441.1%

How does CELU drawdown profile look like?

CELU Financial Health

Current Ratio

0.19

Debt/Equity

0.56

Debt/Cashflow

-3.75

CELU Investor Care

Shares Dilution (1Y)

30.12%

Diluted EPS (TTM)

-0.99

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	16.0M	15.1M	14.8M	0
2022	24.6M	25.2M	18.7M	18.0M
2021	13.5M	12.5M	19.7M	21.3M
2020	18.9M	0	16.6M	14.3M
2019	0	0	0	21.1M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Celularity Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 13, 2024	beers david c	sold (taxes)	-1,479	4.11	-360	chief financial officer
Apr 13, 2024	brigido stephen	sold (taxes)	-1,101	4.11	-268	pres, functional regeneration
Apr 13, 2024	hariri robert j	sold (taxes)	-4,742	4.11	-1,154	chief executive officer
Apr 13, 2024	fletcher kyle	sold (taxes)	-82.2	4.11	-20.00	see remarks
Apr 13, 2024	haines john r	sold (taxes)	-2,367	4.11	-576	see remarks
Mar 15, 2024	fletcher kyle	sold (taxes)	-3,504	5.68	-617	see remarks
Feb 17, 2024	beers david c	sold (taxes)	-19,082	0.434	-43,968	chief financial officer
Feb 17, 2024	haines john r	sold (taxes)	-30,531	0.434	-70,350	see remarks
Feb 17, 2024	kilcoyne adrian	sold (taxes)	-22,898	0.434	-52,762	chief medical officer
Feb 17, 2024	brigido stephen	sold (taxes)	-14,200	0.434	-32,720	pres, functional regeneration

Which funds bought or sold CELU recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 23, 2024	Global Retirement Partners, LLC	new	-	1,569	1,569	-%
Apr 23, 2024	Global Retirement Partners, LLC	sold off	-100	-600	-	-%
Apr 19, 2024	Financial Perspectives, Inc	sold off	-100	-424	-	-%
Apr 19, 2024	Financial Perspectives, Inc	new	-	894	894	-%
Apr 16, 2024	Capital Asset Advisory Services LLC	sold off	-100	-6,185	-	-%
Mar 21, 2024	HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND	unchanged	-	8,610	13,930	-%
Mar 11, 2024	VANGUARD GROUP INC	added	7.43	151,808	923,595	-%
Feb 26, 2024	Privium Fund Management B.V.	reduced	-1.98	34,732	50,346	0.01%
Feb 16, 2024	Context Capital Management, LLC	unchanged	-	5,998,000	6,000,000	-%
Feb 15, 2024	GTS SECURITIES LLC	sold off	-100	-280	-	-%

Are Funds Buying or Selling CELU?

Are funds buying CELU calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own CELU

No. of Funds

Unveiling Celularity Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Mar 15, 2024	dragasac ltd	27.6%	6,335,630	SC 13D/A
Feb 08, 2024	united therapeutics corp	4.11%	7,968,848	SC 13G/A
Jan 17, 2024	dragasac ltd	27.8%	63,356,326	SC 13D/A
Oct 05, 2023	sorrento therapeutics, inc.	2.6%	5,050,427	SC 13G/A
Jun 22, 2023	dragasac ltd	19.6%	36,592,597	SC 13D/A
Feb 13, 2023	starr international co inc	10.54%	15,281,389	SC 13G/A
Feb 13, 2023	c v starr & co inc	5.27%	7,640,693	SC 13G
Feb 06, 2023	united therapeutics corp	5.50%	7,968,848	SC 13G/A
Feb 03, 2023	united therapeutics corp	6.51%	7,968,848	SC 13G
Feb 04, 2022	weiss asset management lp	0.00%	0	SC 13G/A

Recent SEC filings of Celularity Inc.

View All Filings

Date Filed	Form Type	Document
Apr 22, 2024	8-K	Current Report
Apr 16, 2024	4	Insider Trading
Apr 16, 2024	4	Insider Trading
Apr 16, 2024	4	Insider Trading
Apr 16, 2024	4	Insider Trading
Apr 16, 2024	4	Insider Trading
Apr 01, 2024	NT 10-K	NT 10-K
Mar 19, 2024	4	Insider Trading
Mar 15, 2024	4	Insider Trading
Mar 15, 2024	8-K	Current Report

Peers (Alternatives to Celularity Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	41.6B	6.8B	2.33%	-21.90%	-8.82	6.07	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.1B	1.8B	-0.30%	-28.67%	-41.14	9.91	76.23%	61.08%
BMRN	17.2B	2.4B	8.14%	-4.26%	102.64	7.11	15.42%	18.43%
INCY	11.6B	3.7B	-9.39%	-31.39%	19.44	3.14	8.87%	75.42%
MID-CAP
APLS	5.9B	396.6M	-12.04%	-45.12%	-11.11	14.81	425.83%	18.94%
BBIO	4.4B	-	-13.93%	67.39%	-6.74	60.35	54.84%	-34.79%
AXSM	3.4B	270.6M	-9.40%	-0.33%	-14.09	12.46	440.80%	-27.84%
ARWR	2.9B	240.7M	-12.61%	-20.79%	-9.72	12.18	-1.03%	-92.09%
ACAD	2.7B	726.4M	-6.74%	-16.88%	-44.6	3.76	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-6.36%	-10.84%	24.96	4.48	85.90%	-14.05%
NVAX	580.8M	983.7M	-10.64%	-48.02%	-1.07	0.59	-50.36%	17.16%
CRBP	372.9M	881.7K	8.01%	271.09%	-8.36	466.16	-77.61%	-5.33%
INO	237.4M	4.9M	-10.76%	0.48%	-1.76	48.79	-54.97%	51.71%
IBIO	6.6M	2.1M	76.15%	62.71%	-0.24	2.14	-13.45%	66.37%

Celularity Inc. News

Latest updates

Celularity Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q1	2019Q4
Revenue	28.9%	3,786,000	2,938,000	3,935,000	4,129,000	4,135,000	3,776,000	5,935,000	4,856,000	10,622,000	3,197,000	2,660,000	3,243,000	3,355,000	4,208,000	-
Operating Expenses	-	-	-	-	-	-	-	-	-	-	1,538,681	47,055,000	153,063,643	208,305	25,204,000	284,958,625
S&GA Expenses	-16.2%	10,748,000	12,826,000	13,934,000	19,080,000	14,907,000	15,574,000	16,460,000	13,208,000	21,644,000	28,863,000	7,626,000	5,973,000	8,327,000	9,450,000	-
R&D Expenses	-39.8%	5,182,000	8,604,000	16,951,000	10,990,000	20,351,000	25,349,000	21,673,000	24,687,000	23,765,000	22,911,000	16,990,000	13,924,000	11,217,000	11,762,000	-
EBITDA Margin	-140.6%	-11.62	-4.83	1.42	1.32	-0.24	1.61	-2.93	-4.27	-7.40	-19.43	-14.19	-10.02	-	-	-
Interest Expenses	-100.0%	-	822,000	251,000	-	-	-	-	-	-	-	752,000	-	-	-	-
Income Taxes	-	-	-	-	13,000	-17,000	17,000	-	9,000	-16,350	43,700	-	-4,699,415	15,000	4,653,000	-
Earnings Before Taxes	-95.8%	-93,876,000	-47,949,000	-64,017,000	24,447,000	4,782,000	47,843,000	-62,867,000	-4,020,000	49,938,000	-64,477,000	-81,539,000	-57,890,496	-46,310,000	-34,853,000	-270,216,413
EBT Margin	-124.4%	-12.27	-5.47	0.82	0.79	-0.76	1.23	-3.31	-4.69	-7.81	-20.09	-14.80	-10.59	-22.73	-15.59	-
Net Income	-95.8%	-93,876,000	-47,949,000	-64,017,000	24,434,000	4,799,000	47,826,000	-62,867,000	-4,040,000	49,938,000	-64,477,000	-81,539,000	3,910,000	-46,325,000	-30,200,000	-213,636,706
Net Income Margin	-124.4%	-12.27	-5.47	0.82	0.79	-0.76	1.23	-3.31	-4.69	-4.67	-15.13	-19.42	-14.58	-26.62	-12.46	-
Free Cashflow	22.7%	-8,550,000	-11,058,000	-15,204,000	-30,364,000	-39,283,000	-37,758,000	-35,707,000	-34,348,000	-35,884,000	-19,508,000	-26,559,000	-26,203,000	-49,416,990	-29,251,000	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																			(In Millions)
Description	(%) Q/Q	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2018Q4
Assets	-36.2%	157	246	362	401	437	429	434	414	448	128	405	431	292	292	293	521	291	290	-
Current Assets	-8.5%	16.00	18.00	25.00	34.00	63.00	75.00	76.00	59.00	91.00	0.00	43.00	72.00	1.00	1.00	1.00	37.00	1.00	1.00	0.00
Cash Equivalents	-91.1%	0.00	3.00	3.00	14.00	57.00	53.00	63.00	52.00	87.00	23.00	38.00	70.00	96.00	1.00	117	44.00	1.00	1.00	23.00
Inventory	-14.0%	5.00	6.00	5.00	5.00	5.00	25.00	15.00	10.00	6.00	-	5.00	4.00	-	-	-	3.00	-	-	-
Net PPE	-2.7%	71.00	73.00	74.00	76.00	77.00	78.00	78.00	91.00	91.00	-	90.00	90.00	-	-	-	66.00	-	-	-
Goodwill	-91.8%	7.00	90.00	90.00	120	123	123	123	123	123	-	123	123	-	-	-	127	-	-	-
Liabilities	-0.8%	127	128	207	202	273	279	344	315	352	47.00	467	412	34.00	23.00	12.00	384	24.00	21.00	-
Current Liabilities	30.3%	85.00	65.00	66.00	62.00	69.00	33.00	26.00	26.00	29.00	7.00	25.00	27.00	0.00	0.00	0.00	21.00	0.00	0.00	0.00
Short Term Borrowings	-16.7%	14.00	17.00	31.00	38.00	39.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Long Term Debt	-100.0%	-	17.00	5.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Shareholder's Equity	-74.5%	30.00	119	156	199	164	150	90.00	99.00	96.00	-	-	5.00	5.00	5.00	5.00	5.00	5.00	5.00	0.00
Retained Earnings	-12.4%	-851	-757	-709	-645	-669	-674	-722	-663	-659	-47.41	-645	-563	-13.80	-3.26	0.00	-355	4.00	-0.48	0.00
Additional Paid-In Capital	0.6%	879	874	862	844	834	825	812	763	756	-	33.00	32.00	14.00	2.00	-0.34	28.00	1.00	4.00	0.00
Shares Outstanding	7.1%	194	181	165	149	138	135	130	124	106	24.00	24.00	19.00	18.00	26.00	24.00	24.00	-	-	-
Float	-	-	-	-	-	-	227	-	-	-	128	-	-	-	293	-	-	-	297	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3
Cashflow From Operations	24.5%	-8,322	-11,027	-14,995	-29,585	-37,720	-36,318	-34,253	-32,045	-34,771	-18,200	-25,080	-16,831	-45,587	24,648	-25,422	-65,918	-679	-194	-676*	-543*	-
Cashflow From Investing	-635.5%	-228	-31.00	-3,209	-779	-1,563	-1,440	-1,454	-2,303	-1,113	-1,008	-1,479	-9,372	-4,016	4,403	-3,829	-	-	-	-	-	-
Cashflow From Financing	2.3%	5,739	5,610	12,759	1,685	43,939	27,719	46,495	-1,014	100,403	4,015	-4,842	-317	-	-	102,550	-169,585	-	288,844	-5.15	25.00	-
Buy Backs	-	-	-	-	-	-	-75.00	-11.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-

CELU Income Statement

2023-09-30

Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Net revenues
Total revenues	$ 3,786,000	$ 4,135,000	$ 10,659,000	$ 13,846,000
Cost of revenues (excluding amortization of acquired intangible assets)
Research and development	5,182,000	20,351,000	30,737,000	67,373,000
Software cease-use costs	243,000		24,161,000
Selling, general and administrative	10,748,000	14,907,000	37,508,000	46,941,000
Change in fair value of contingent consideration liability	0	(33,243,000)	(104,339,000)	(73,441,000)
Goodwill impairment	82,714,000	0	112,347,000	0
IPR&D impairment	0	0	107,800,000	0
Amortization of acquired intangible assets	553,000	553,000	1,640,000	1,640,000
Total operating expenses	103,042,000	9,781,000	216,261,000	56,931,000
Loss from operations	(99,256,000)	(5,646,000)	(205,602,000)	(43,085,000)
Other income (expense):
Interest income	23,000	108,000	205,000	155,000
Interest expense	(971,000)	0	(2,352,000)	0
Change in fair value of warrant liabilities	5,187,000	9,333,000	6,788,000	31,613,000
Change in fair value of debt	2,003,000	(291,000)	(354,000)	(291,000)
Other income (expense), net	(862,000)	1,278,000	(4,527,000)	1,366,000
Total other income (expense)	5,380,000	10,428,000	(240,000)	32,843,000
(Loss) income before income taxes	(93,876,000)	4,782,000	(205,842,000)	(10,242,000)
Income tax benefit	0	(17,000)	0	0
Net (loss) income	(93,876,000)	4,799,000	(205,842,000)	(10,242,000)
Change in fair value of debt due to change in credit risk, net of tax	0	236,000	2,541,000	236,000
Other comprehensive income	0	236,000	2,541,000	236,000
Comprehensive (loss) income	$ (93,876,000)	$ 5,035,000	$ (203,301,000)	$ (10,006,000)
Net (loss) income per share - basic	$ (0.5)	$ 0.03	$ (1.19)	$ (0.07)
Weighted average shares outstanding - basic	188,317,262	142,676,953	173,536,134	137,787,645
Net (loss) income per share - diluted	$ (0.5)	$ 0.03	$ (1.19)	$ (0.07)
Weighted average shares outstanding - diluted	188,317,262	150,546,268	173,536,134	137,787,645
Product Sales and Rentals
Net revenues
Total revenues	$ 1,684,000	$ 1,041,000	$ 3,633,000	$ 2,920,000
Cost of revenues (excluding amortization of acquired intangible assets)
Cost of revenues	557,000	812,000	1,486,000	1,711,000
Services
Net revenues
Total revenues	1,427,000	1,405,000	4,062,000	4,061,000
Cost of revenues (excluding amortization of acquired intangible assets)
Cost of revenues	398,000	899,000	1,355,000	3,112,000
Licenses, Royalties and Other
Net revenues
Total revenues	675,000	1,689,000	2,964,000	6,865,000
Cost of revenues (excluding amortization of acquired intangible assets)
Cost of revenues	$ 2,647,000	$ 5,502,000	$ 3,566,000	$ 9,595,000

CELU Balance Sheet

2023-09-30

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 273	$ 13,966
Accounts receivable, net of allowance of $2,188 and $1,789 as of September 30, 2023 and December 31, 2022, respectively	4,114	4,452
Notes receivable	2,072	2,514
Inventory	4,934	5,308
Prepaid expenses and other current assets	5,105	7,262
Total current assets	16,498	33,502
Property and equipment, net	70,647	75,655
Goodwill	7,347	119,694
Intangible assets, net	11,554	120,994
Right-of-use assets - operating leases	11,039	13,060
Restricted cash	14,825	14,836
Inventory, net of current portion	24,928	22,949
Other long-term assets	354	376
Total assets	157,192	401,066
Current liabilities:
Accounts payable	12,931	5,810
Accrued expenses and other current liabilities	10,239	9,069
Accrued R&D software	24,000	7,333
Short-term debt ($14,006 at fair value and $16,623 unpaid principal balance at September 30, 2023)	14,006	37,603
Other short-term debt	2,032
Other short-term debt - related party	1,017
Short-term debt - related parties	17,949
Deferred revenue	2,458	2,273
Total current liabilities	84,632	62,088
Deferred revenue, net of current portion	3,099	2,219
Acquisition-related contingent consideration	1,606	105,945
Noncurrent lease liabilities - operating	26,074	27,985
Noncurrent accrued R&D software	7,494
Warrant liabilities	3,735	3,598
Deferred income tax liabilities	9	9
Other liabilities	296	321
Total liabilities	126,945	202,165
Commitments and Contingencies (Note 9)
Stockholders’ equity
Preferred stock, $0.0001 par value, 10,000,000 shares authorized, none issued and outstanding at September 30, 2023 and December 31, 2022
Common stock, $0.0001 par value, 730,000,000 shares authorized, 193,659,133 issued and outstanding as of September 30, 2023; 730,000,000 shares authorized, 148,921,187 issued and outstanding as of December 31, 2022	19	15
Additional paid-in capital	879,171	844,373
Accumulated other comprehensive income	2,395	9
Accumulated deficit	(851,338)	(645,496)
Total stockholders’ equity	30,247	198,901
Total liabilities and stockholders' equity	$ 157,192	$ 401,066

About Celularity Inc.

Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease. It is also developing CYCART-201 for the treatment of NHL and MCL, and human epidermal growth factor receptor 2 positive cancers; CYNK-301, a next generation chimeric antigen receptor-natural killer (CAR-NK) for treating relapse refractory AML; CYNK-302, a CAR-NK to treat non-small cell lung cancer; and pExo-001, a human postpartum placenta derived exosome product for the treatment of osteoarthritis. It also produces, sells, and licenses products that are used in surgical and wound care markets, such as Biovance, Biovance 3L, Interfyl, and Centaflex; and collects and stores stem cells from umbilical cords and placentas under the LifebankUSA brand. The company has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; and research collaboration services agreement with Regeneron Pharmaceuticals, Inc. to support the research of allogeneic cell therapy candidates. The company was founded in 1998 and is based in Florham Park, New Jersey.

CEO	Dr. Robert Joseph Hariri M.D., Ph.D.
WEBSITE	celularity.com
INDUSTRY	Biotechnology
EMPLOYEES	225

Celularity Inc. Frequently Asked Questions

What is the ticker symbol for Celularity Inc.? What does CELU stand for in stocks?

CELU is the stock ticker symbol of Celularity Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Celularity Inc. (CELU)?

As of Tue Apr 23 2024, market cap of Celularity Inc. is 622.04 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CELU stock?

You can check CELU's fair value in chart for subscribers.

What is the fair value of CELU stock?

You can check CELU's fair value in chart for subscribers. The fair value of Celularity Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Celularity Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for CELU so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Celularity Inc. a good stock to buy?

The fair value guage provides a quick view whether CELU is over valued or under valued. Whether Celularity Inc. is cheap or expensive depends on the assumptions which impact Celularity Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CELU.

What is Celularity Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Apr 23 2024, CELU's PE ratio (Price to Earnings) is -3.77 and Price to Sales (PS) ratio is 46.26. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CELU PE ratio will change depending on the future growth rate expectations of investors.